Breaking AI & Tech News Analyzed

Liverpool's struggles continued as they were thoroughly outplayed by Paris Saint-Germain in a 2-0 defeat. The Reds had a dismal 28% possession and failed to register a single shot on target. Manager Arne Slot acknowledged that his team had been 'ripped apart' at times and admitted to employing negative tactics to keep the tie alive for the second leg.PSG's dominance was evident throughout the match, with their midfielder Vitinha standing out. Despite their superior performance, PSG were unable to capitalize on their chances, allowing Liverpool to stay in the tie. Liverpool's Virgil van Dijk has called on fans to make a significant impact in the return leg at Anfield, but it remains to be seen if the team can mount a successful comeback.The defeat has raised questions about Slot's approach and the team's ability to compete with top-tier opponents. The return leg next Tuesday promises to be a crucial encounter, with Liverpool needing a significant turnaround to advance to the next round of the Champions League.

What would Henrik Ibsen’s iconic heroine Nora look like in today’s Britain? In this bold re‑imagining, playwright Anya Reiss transports the 19th‑century drama into a world of high‑salary banking, social‑media façades and post‑pandemic consumer excess. Set against a sleek, white‑goods‑strewn stage designed by Hyemi Shin, the story follows Nora (played by Romola Garai) as the wife of a lucrative London banker, Torvald (Tom Mothersdale), who is also battling drug addiction. Though presented as a “trophy wife”, Nora is far sharper than her husband realises – she has secretly rescued the family from financial collapse and funded Torvald’s recovery, all while maintaining a veneer of festive, pre‑Christmas splurging. The familiar Ibsen plot points survive the update: a blackmail threat from Torvald’s colleague Nils Krogstad (James Corrigan) and a visit from the destitute, marriage‑for‑money‑failed friend Kristine (Thalissa Teixeira). Their interactions expose the tension between outward affluence and hidden desperation. Reiss’s version is unmistakably contemporary, peppering dialogue with references to Instagram, a stock market rattled by conflict in the Middle East, and the relentless pursuit of material status. This backdrop reframes the marital power struggle as a clash of class and modern capitalism, asking whether love can ever be insulated from market forces. Despite the heavy thematic load, the cast delivers a series of compelling performances. Garai’s Nora oscillates between calculated seduction – even donning a provocative nurse’s outfit for a flirtatious dance – and a keen intellect that refuses to be reduced to a mere commodity. Her portrayal suggests that, for Nora, the body has become a form of currency, yet she remains acutely aware of the performative nature of both marriage and motherhood. Notably, the children appear only through baby‑monitor audio, a deliberate choice that underscores the couple’s emotional distance and mirrors the original’s focus on Nora’s internal emancipation. The climax arrives in a charged confrontation where Nora questions, “Is love meant to be subject to the market?” The line encapsulates Reiss’s preoccupation with the commodification of intimacy, even as it feels like a summarising refrain rather than a fresh revelation. Ultimately, the production offers a nuanced, if occasionally over‑engineered, vision of Ibsen’s feminist aspirations. It hints at a future where Nora and Torvald might seek couples therapy to untangle their financial and emotional entanglements – a decidedly modern resolution. A Doll’s House runs at the Almeida Theatre, London, until 23 May.

Meta announced the launch of Muse Spark, the debut artificial‑intelligence model from the company’s ambitious "superintelligence" squad that was assembled last year with a multi‑billion‑dollar budget. The team, spearheaded by former Scale AI chief Alex Wang—brought on board in a $14.3 bn acquisition—has been offered compensation packages running into the hundreds of millions to attract top talent. Muse Spark is the first installment of the internally codenamed "Avocado" series. For now, the model is accessible only through Meta’s AI app and website, but Meta says it will soon supplant the existing Llama models that power chatbots on WhatsApp, Instagram, Facebook and the firm’s smart‑glasses lineup. Unlike earlier open releases of Llama, Meta has kept Muse Spark’s architecture details under wraps, offering a private preview to a select group of unnamed partners. In a blog post, Meta described the system as "small and fast by design, yet capable enough to reason through complex questions in science, math and health," positioning it as a solid foundation for future, larger versions. Independent testing shows Muse Spark narrowing the gap with leading models from Google, OpenAI and Anthropic in language and visual comprehension, though it still trails in coding and abstract reasoning tasks. The model placed tied for fourth on a comprehensive AI benchmark compiled by Artificial Analysis. CEO Mark Zuckerberg had previously cautioned investors that early releases would be modest but would demonstrate a "rapid trajectory." Wang echoed this sentiment on social media, acknowledging "rough edges" that will be refined over time and confirming that bigger variants are already in development, with some slated for open release. Beyond performance metrics, Meta hinted at commercial ambitions, embedding shopping suggestions directly into its AI chatbot to guide users toward purchasable items. With over 3.5 billion active users across its platforms, the company hopes AI‑driven personal tasks will boost engagement and create a competitive edge over rivals with smaller user bases. Practical use‑cases highlighted include estimating meal calories from a photo, virtually placing a mug on a shelf via augmented reality, and a new "Contemplating Mode" that runs multiple agents simultaneously—mirroring advanced reasoning features seen in Google’s Gemini Deep Think and OpenAI’s GPT‑Pro. Meta says this mode could, for example, help a family plan a vacation by having one agent draft an itinerary while another scouts kid‑friendly activities.

UK Prime Minister Keir Starmer has expressed his concern over Israel's ongoing attacks on Lebanon, emphasizing that they 'shouldn't be happening' and must stop immediately. During his visit to the Middle East, Starmer called for the Iran conflict to be a turning point for the UK's future security. In an article for the Guardian, Starmer outlined the need for a fundamental reset in the UK's approach to make the country more resilient, including boosting defense and strengthening ties with Europe. He highlighted the importance of not being drawn into offensive military action, while rebuilding European alliances and increasing defense capacity. Starmer's comments echo those of Yvette Cooper, the foreign secretary, and John Healey, the defense secretary, indicating a potential divergence between the UK and the US under Donald Trump over the Iran conflict. The UK has been adamant that the Strait of Hormuz must remain free of tolls or levies, contrary to Trump's suggestion of a 'joint venture' between the US and Iran. Starmer criticized Israel's intensified bombing in Lebanon, which has resulted in over 250 deaths. He emphasized that the issue is 'a matter of principles' and not a technical one, dismissing arguments that the attacks are not part of the ceasefire agreement. The UK's stance has been to support the ceasefire and advocate for the inclusion of Lebanon in the agreement. Starmer also emphasized the need for the UK to be closer to the EU on defense, security, trade, and energy to strengthen the economy and make it more resilient. He highlighted that the war in Iran must be a 'line in the sand' and that the UK's response will define its future for a generation.

Northampton Saints' JJ van der Mescht is a force to be reckoned with on the rugby field. Standing at an impressive 6ft 7in and weighing 23st, he is the joint-heaviest player in the Premiership. His size and strength make him a major collision threat, and his skills have earned him a spot in South Africa's alignment squad.Van der Mescht, 26, has a unique playing style that has drawn comparisons to Australia's Will Skelton. He is too heavy to be lifted regularly in the lineout, but his ability to give his team vital post-contact metres makes him a valuable asset. His director of rugby, Phil Dowson, describes him as 'a fly-half trapped in a second-row's body.'The South African lock has a personal connection with Bath prop Thomas du Toit, with whom he played as a youngster at the Sharks in Durban. He is eager to bump into his old friend during the match, and he expects a fierce encounter. Van der Mescht has dropped seven kilos since joining Northampton and currently weighs 146kg. He credits the club with rekindling his love for rugby, saying that he now enjoys the game again and feels happy.Van der Mescht's impressive performance has put him back on the South African radar, and he may be considered for the Springboks in the future. For now, he is focused on helping Northampton overcome Bath in the Champions Cup quarter-final. The match could be a prelude to another battle between England's top two sides in the Premiership final.

Gordon Elliott opened the Grand National meeting with a strong performance, securing a Grade One double on Thursday. His horse, Brighterdaysahead, won the Aintree Hurdle by two-and-a-quarter lengths, defeating Dan Skelton's The New Lion. This victory confirms the form of the Champion Hurdle at Cheltenham, where Brighterdaysahead finished second.Elliott now has five runners in the Grand National on Saturday, and a fourth success in the world’s most famous steeplechase would put him in a share of the all-time record. The trainer is optimistic about his chances with horses like Pied Piper, who was initially promoted to the final field but later ruled out.In other news, Coming Up Easy is a strong contender for the Topham Handicap Chase on Friday, with a good chance of winning at around 14-1. The eight-year-old horse had a useful performance in a Listed handicap chase last summer and could be a good bet.Elliott's success on Thursday was a significant boost to his Grand National hopes. He also had a win in the juvenile hurdle with Mange Tout, trained by him. Meanwhile, Willie Mullins, who won all four Grade One events on the opening day last year, had a quieter day this time around.

Amazon announced that, effective 20 May 2026, it will stop delivering software updates to Kindle and Kindle Fire devices launched in 2012 or earlier. The decision targets a range of models, from the original 2007 Kindle to the first‑generation Kindle Paperwhite and early Kindle Fire tablets. According to the company, owners will retain the ability to read books already stored on their devices, and their Amazon accounts will remain usable through mobile and desktop applications. However, a factory reset on the affected units will render them inoperable for new purchases, borrowing, or downloads. Amazon is offering discounts to encourage users to upgrade to newer hardware, acknowledging that many of the devices have been supported for 14‑18 years. The move has ignited a wave of criticism online, with users describing their still‑functional e‑readers as being reduced to "paperweights" and accusing the retailer of fostering large‑scale waste. Ugo Vallauri of the Restart Project—a UK‑based repair advocacy group—told the BBC that manufacturers often cite performance improvements when ending support, but this does not justify "soft‑bricking" millions of functional devices. He estimates the impact could affect roughly 2 million e‑readers, representing about 3 % of Kindle users, potentially creating more than 624 tons of e‑waste. Tech analyst Paolo Pescatore described the decision as "understandable from a security and support perspective," noting that the hardware of these older models was not designed for today's data‑intensive services. In summary, Amazon's phase‑out underscores the tension between extending product lifespans and keeping pace with rapid technological advancement, while raising environmental questions about the fate of legacy devices.

Renowned British perfumer Jo Malone has expressed her surprise and sadness after being sued for over £200,000 in damages by Estée Lauder Companies, the owner of her former perfume brand, Jo Malone London. The lawsuit claims that Malone infringed trademarks by using her name on fragrances she created for the fashion chain Zara.In 1999, Malone sold her perfume brand to Estée Lauder, a US-based multinational cosmetics group that owns brands such as M.A.C, Bobbi Brown, and Estée Lauder. As part of the agreement, Malone was prohibited from using her name for certain commercial activities, including marketing fragrances.Malone stepped down as creative director of Jo Malone London in 2006 and later regretted selling the rights to her name, calling it the “biggest mistake of my life.” In 2011, after a non-compete clause ended, Malone launched the Jo Loves brand. In 2019, Jo Loves collaborated with Zara on a line of eight fragrances, priced at £35.99 each.Estée Lauder took issue with the packaging of these fragrances, which clearly stated that they were created by Jo Malone CBE, founder of Jo Loves. The company claims that this use of Malone's name undermines the brand equity of Jo Malone London and is seeking damages of over £200,000.In response, Malone has defended her use of her name, stating, “My name is Jo Malone. I am the person, the fragrance creator, the entrepreneur, the cancer survivor, the person. I never expected to receive a high court claim with my name on it.” She emphasized that when Zara approached her, they did so as an individual, not as a company or brand.Malone added, “I sold a company, I did not sell myself.” She expressed her concerns about the implications of the lawsuit, asking, “Where do I go from here? Who can I be? I can’t stop being a person. Nobody can stop being the character and the person that you are.”

A 47‑year‑old woman who had endured three life‑threatening autoimmune diseases for more than a decade is now living a near‑normal life after an experimental CAR‑T cell therapy reset her immune system at University Hospital Erlangen in Germany.Before the procedure she had exhausted nine different treatments with no lasting benefit, relying on daily blood transfusions and continuous anticoagulation to manage her illnesses.Within weeks of the infusion, doctors observed rapid improvement in all three conditions—a world‑first outcome. She has remained in treatment‑free remission for 14 months and has largely returned to everyday activities.Prof Fabian Müller, who led the team, called the speed and depth of the response “remarkable” and said the therapy “significantly improved her quality of life.” He emphasized that clinical trials are required to determine how durable the effect is and whether it can help other autoimmune patients.The patient suffered from three distinct disorders: autoimmune haemolytic anaemia (AIHA), where rogue immune cells destroy red blood cells; immune thrombocytopenia (ITP), which depletes platelets and raises bleeding risk; and antiphospholipid syndrome (APS), which promotes dangerous blood clots. All three stem from malfunctioning B‑cells.With no conventional options left, doctors turned to CAR‑T therapy, a technique that has revolutionised treatment for certain cancers. They harvested her white‑blood cells, isolated the T‑cells, engineered them to recognise the CD19 protein on B‑cells, and reinfused the modified cells.The engineered T‑cells swiftly eliminated the pathogenic B‑cells. She received her last blood transfusion a week after treatment and was able to perform routine tasks within two weeks. Follow‑up tests showed a reconstituted, healthy B‑cell population, suggesting an immune reset. The findings were published in the journal Med.She still exhibits a mildly low white‑cell count and slightly elevated liver enzymes, which researchers attribute to the cumulative impact of prior therapies rather than the CAR‑T product.Rheumatology expert Prof Ben Parker of Manchester University NHS Foundation Trust described the case as encouraging, noting that “the prolonged response off normal therapy suggests there has been an immune reset.” However, he warned that case reports alone cannot confirm efficacy and highlighted ongoing trials for lupus, myositis, multiple sclerosis, systemic sclerosis, vasculitis, and other autoimmune conditions.